For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DPB865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 7, 2026.
Mapping Therapeutic Directions in DLBCL: Team Strategies for Prognostic Assessment and Implications for Targeted Therapy and Other Innovative Options
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure information is available at the beginning of the video presentation.
View all episodes
By PVI, PeerView Institute for Medical Education
4
1010 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DPB865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 7, 2026.
Mapping Therapeutic Directions in DLBCL: Team Strategies for Prognostic Assessment and Implications for Targeted Therapy and Other Innovative Options
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure information is available at the beginning of the video presentation.
136 Listeners
5 Listeners
4 Listeners
3 Listeners
10 Listeners
5 Listeners
28 Listeners
10 Listeners
3 Listeners
2 Listeners
4 Listeners
2 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
323 Listeners
39 Listeners
2 Listeners
116 Listeners
2 Listeners
500 Listeners
57 Listeners
3,331 Listeners
2 Listeners
44 Listeners
21 Listeners
367 Listeners
52 Listeners
56 Listeners
185 Listeners